Program
REGN9220
A development code.
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse, led by Regeneron Pharmaceuticals.
Furthest: phase 2, since Oct 14, 20261 company-led study, 1 open or runningNext primary completion: Nov 1, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 11 open or running | phase 2since Oct 14, 2026 | Oct 14, 2026 | Nov 1, 2029phase 2 · NCT07887750 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2026First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT07887750 · 36 planned
Ahead
- Nov 1, 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07887750
TargetBeta
“Phase 1 Trial to Investigate the Safety and Tolerability of REGN9220, an Anti-CD22 X Anti-4-1BB Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Aggressive B-Cell Non-Ho…”study text, by rule · the study
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07887750Lymphoma, Large B-Cell, Diffuse | 2 | Not yet recruiting | Nov 1, 2029 | 36 |
How it is read
Names in the registry
- “REGN9220”, 1 entry
Codes read as this program: REGN9220.
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.